Martin E. W. Hemels
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Martin E. W. Hemels has a total of 227 co-authors. Here are the top co-authors by number of shared publications:
- Ron Pisters
Department of Cardiology, Rijnstate Hospital , Arnhem
7 shared publications - Michiel Rienstra
Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands
6 shared publications - Dominik Linz
Department of Cardiology, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Centre , Maastricht
5 shared publications - Menno V. Huisman
Leiden University Medical Center
5 shared publications - Bao-Oanh Nguyen
University Medical Centre Groningen
4 shared publications - Frans Hendrik Rutten
Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands
4 shared publications
Latest Publications
- Open Access
- 16 September 2026
- Published by Springer Nature in Netherlands Heart Journal
- Vol. 34 (10) , 329
Obesity and cardiovascular disease: Time for a paradigm shift
- 16 September 2026
- Published by Springer Nature in Netherlands Heart Journal
- Vol. 34 (10) , 329
Open AccessObesity and cardiovascular disease: Time for a paradigm shift
- Open Access
- 18 May 2026
- Published by Springer Nature in Journal of Thrombosis and Thrombolysis
- Vol. 59 (6) , 1-13
Edoxaban for atrial fibrillation in patients with atherosclerotic disease in daily clinical practice
To estimate major clinical event rates for patients with atrial fibrillation (AF) and atherosclerotic disease treated with edoxaban in routine practice, and to evaluate how well such patients were represented in ENGAGE AF-TIMI 48, the seminal randomized trial comparing edoxaban against warfarin for AF. ETNA-AF-Europe is a prospective cohort of AF patients receiving edoxaban in routine care. We compared patients with coronary or peripheral artery disease (CAD/PAD) to: (1) those without CAD/PAD in ETNA-AF-Europe, and (2) CAD/PAD patients in ENGAGE AF-TIMI 48. Of 13,164 patients in ETNA-AF-Europe, 23.3% had CAD/PAD. Compared with those without, patients with CAD/PAD had higher rates of stroke/systemic embolism (0.87%/year vs. 0.59%/year; HR 1.5, 95%-CI 1.14–1.88), acute coronary syndrome (1.24%/year vs. 0.37%/year; HR 3.3, 95%-CI 2.60–4.27), major bleeding (1.06%/year vs. 0.81%/year; HR 1.3, 95%-CI 1.04–1.63), cardiovascular death (1.59%/year vs. 0.85%/year; HR 1.9, 95%-CI 1.54–2.26), and all-cause death (6.02%/year vs. 3.53%/year; HR 1.7, 95%-CI 1.55–1.89). Compared with CAD/PAD patients in ENGAGE-AF TIMI-48, those in ETNA-AF-Europe had fewer cardiovascular comorbidities, less prevalent aspirin use (20.2% vs. 50.3%), and lower rates of stroke/systemic embolism (0.87%/year vs. 1.5%/year), major bleeding (1.04%/year vs. 3.0%/year), and cardiovascular death (1.59%/year vs. 3.7%), but higher non-cardiovascular mortality (4.43%/year vs. 1.6%/year). In routine practice, deaths and bleeding were the most common events in edoxaban-treated patients with AF. This pattern was consistent between those with and without atherosclerosis. ENGAGE-AF TIMI-48 participants with CAD/PAD had substantially higher cardiovascular but lower non-cardiovascular risks than those treated in daily practice. Trial registration number: NCT02944019 (ClinicalTrials.gov Identifier). Graphical Abstract
- 18 May 2026
- Published by Springer Nature in Journal of Thrombosis and Thrombolysis
- Vol. 59 (6) , 1-13
Open AccessEdoxaban for atrial fibrillation in patients with atherosclerotic disease in daily clinical practice
To estimate major clinical event rates for patients with atrial fibrillation (AF) and atherosclerotic disease treated with edoxaban in routine practice, and to evaluate how well such patients were represented in ENGAGE AF-TIMI 48, the seminal randomized trial comparing edoxaban against warfarin for AF. ETNA-AF-Europe is a prospective cohort of AF patients receiving edoxaban in routine care. We compared patients with coronary or peripheral artery disease (CAD/PAD) to: (1) those without CAD/PAD in ETNA-AF-Europe, and (2) CAD/PAD patients in ENGAGE AF-TIMI 48. Of 13,164 patients in ETNA-AF-Europe, 23.3% had CAD/PAD. Compared with those without, patients with CAD/PAD had higher rates of stroke/systemic embolism (0.87%/year vs. 0.59%/year; HR 1.5, 95%-CI 1.14–1.88), acute coronary syndrome (1.24%/year vs. 0.37%/year; HR 3.3, 95%-CI 2.60–4.27), major bleeding (1.06%/year vs. 0.81%/year; HR 1.3, 95%-CI 1.04–1.63), cardiovascular death (1.59%/year vs. 0.85%/year; HR 1.9, 95%-CI 1.54–2.26), and all-cause death (6.02%/year vs. 3.53%/year; HR 1.7, 95%-CI 1.55–1.89). Compared with CAD/PAD patients in ENGAGE-AF TIMI-48, those in ETNA-AF-Europe had fewer cardiovascular comorbidities, less prevalent aspirin use (20.2% vs. 50.3%), and lower rates of stroke/systemic embolism (0.87%/year vs. 1.5%/year), major bleeding (1.04%/year vs. 3.0%/year), and cardiovascular death (1.59%/year vs. 3.7%), but higher non-cardiovascular mortality (4.43%/year vs. 1.6%/year). In routine practice, deaths and bleeding were the most common events in edoxaban-treated patients with AF. This pattern was consistent between those with and without atherosclerosis. ENGAGE-AF TIMI-48 participants with CAD/PAD had substantially higher cardiovascular but lower non-cardiovascular risks than those treated in daily practice. Trial registration number: NCT02944019 (ClinicalTrials.gov Identifier). Graphical Abstract
- Open Access
- 14 May 2026
- Published by Oxford University Press (OUP) in European Heart Journal Open
- Vol. 6 (3) , oeag078
Design and rationale of the RISC-trial: multicentre R CT to assess i mmediate discharge of s yncope patients admitted to the ( c ardiac) emergency room
Aims: Syncope is responsible for 1–3% of emergency department presentations. The European Society of Cardiology guidelines on syncope recommend a structured initial evaluation to diagnose syncope patients. If the cause of the syncopal event remains unexplained, risk-stratification is applied to distinguish between patients at high risk of serious cardiovascular events and low-risk patients, who can be safely discharged. However, there is a group of patients in whom this risk can currently not be adequately determined, hereafter called intermediate risk. In clinical practice, these patients are either immediately discharged or admitted for 24 h in-hospital cardiac rhythm monitoring. Due to the high cost of admission, immediate discharge could lower healthcare costs, hospital bed utilization, and patient burden. To our knowledge, there is no sufficient scientific basis for the superiority of either. The RISC trial aims to resolve this knowledge gap. Study Design: The RISC trial is an investigator-initiated multicentre prospective randomized controlled trial. A total of 640 predefined low- and intermediate-risk syncope patients are randomized to either immediate discharge or discharge after 24 h in-hospital rhythm monitoring (1:1). The trial is powered to claim non-inferiority of immediate discharge with respect to (non-)fatal composite safety endpoints, which entail arrhythmic disorders, syncope recurrence, and (cardiovascular)death. Furthermore, healthcare costs and quality of life will be evaluated. Conclusion: The RISC trial is a multicentre RCT that aims to gather scientific evidence for immediate discharge of the ESC guideline–based pre-defined low- and intermediate-risk syncope patients in the emergency department. Primary endpoints entail cardiovascular events such as arrhythmias, syncope, and death. This trial is registered at ClinicalTrials.gov with trial-ID: NCT06472375.
- 14 May 2026
- Published by Oxford University Press (OUP) in European Heart Journal Open
- Vol. 6 (3) , oeag078
Open AccessDesign and rationale of the RISC-trial: multicentre R CT to assess i mmediate discharge of s yncope patients admitted to the ( c ardiac) emergency room
Aims: Syncope is responsible for 1–3% of emergency department presentations. The European Society of Cardiology guidelines on syncope recommend a structured initial evaluation to diagnose syncope patients. If the cause of the syncopal event remains unexplained, risk-stratification is applied to distinguish between patients at high risk of serious cardiovascular events and low-risk patients, who can be safely discharged. However, there is a group of patients in whom this risk can currently not be adequately determined, hereafter called intermediate risk. In clinical practice, these patients are either immediately discharged or admitted for 24 h in-hospital cardiac rhythm monitoring. Due to the high cost of admission, immediate discharge could lower healthcare costs, hospital bed utilization, and patient burden. To our knowledge, there is no sufficient scientific basis for the superiority of either. The RISC trial aims to resolve this knowledge gap. Study Design: The RISC trial is an investigator-initiated multicentre prospective randomized controlled trial. A total of 640 predefined low- and intermediate-risk syncope patients are randomized to either immediate discharge or discharge after 24 h in-hospital rhythm monitoring (1:1). The trial is powered to claim non-inferiority of immediate discharge with respect to (non-)fatal composite safety endpoints, which entail arrhythmic disorders, syncope recurrence, and (cardiovascular)death. Furthermore, healthcare costs and quality of life will be evaluated. Conclusion: The RISC trial is a multicentre RCT that aims to gather scientific evidence for immediate discharge of the ESC guideline–based pre-defined low- and intermediate-risk syncope patients in the emergency department. Primary endpoints entail cardiovascular events such as arrhythmias, syncope, and death. This trial is registered at ClinicalTrials.gov with trial-ID: NCT06472375.
- 13 December 2025
- Published by Taylor & Francis in Future Cardiology
- Vol. 22 (1) , 57-63
Clinical implications of the interaction between metabolic risk factors, coronary artery disease and atrial fibrillation
Atrial fibrillation (AF) and coronary artery disease (CAD) frequently coexist due to shared risk factors such as obesity and diabetes. The interrelationship between these diseases carries important therapeutic implications, given the fact that both AF and CAD are associated with an increased risk for cardiovascular events such as stroke, myocardial infarction, heart failure and cardiovascular mortality. In this review, we elucidate our current understanding of the epidemiological and pathophysiological links between AF and CAD, with particular focus on the impact of obesity, diabetes and systemic inflammation as common drivers. We discuss the implications for patient management, including antithrombotic therapy, lifestyle modifications and metabolic risk reduction. Beyond antithrombotic therapy, we highlight the importance of rate and rhythm control strategies in case of coexisting of AF and CAD. Novel pharmacological approaches for patients with CAD and type 2 diabetes, such as GLP-1 receptor agonist and SGLT2 inhibitors, provide additional cardiometabolic benefits by reducing the risk of major adverse cardiovascular events. Finally we propose a framework for integrated management of AF and CAD that aligns with contemporary guidelines and emerging evidence. This holistic approach, including metabolic risk factor modification, represents a paradigm shift in the care of patients with both AF and CAD.
- 13 December 2025
- Published by Taylor & Francis in Future Cardiology
- Vol. 22 (1) , 57-63
Clinical implications of the interaction between metabolic risk factors, coronary artery disease and atrial fibrillation
Atrial fibrillation (AF) and coronary artery disease (CAD) frequently coexist due to shared risk factors such as obesity and diabetes. The interrelationship between these diseases carries important therapeutic implications, given the fact that both AF and CAD are associated with an increased risk for cardiovascular events such as stroke, myocardial infarction, heart failure and cardiovascular mortality. In this review, we elucidate our current understanding of the epidemiological and pathophysiological links between AF and CAD, with particular focus on the impact of obesity, diabetes and systemic inflammation as common drivers. We discuss the implications for patient management, including antithrombotic therapy, lifestyle modifications and metabolic risk reduction. Beyond antithrombotic therapy, we highlight the importance of rate and rhythm control strategies in case of coexisting of AF and CAD. Novel pharmacological approaches for patients with CAD and type 2 diabetes, such as GLP-1 receptor agonist and SGLT2 inhibitors, provide additional cardiometabolic benefits by reducing the risk of major adverse cardiovascular events. Finally we propose a framework for integrated management of AF and CAD that aligns with contemporary guidelines and emerging evidence. This holistic approach, including metabolic risk factor modification, represents a paradigm shift in the care of patients with both AF and CAD.
- Open Access
- 19 July 2025
- Published by Oxford University Press (OUP) in European Journal of Cardiovascular Nursing
- Vol. 25 (1) , 195-197
Digital pulse self-measurement by a photoplethysmography smartphone application in the general population: the ‘#PulseDay in The Netherlands’ awareness campaign
- 19 July 2025
- Published by Oxford University Press (OUP) in European Journal of Cardiovascular Nursing
- Vol. 25 (1) , 195-197
Open AccessDigital pulse self-measurement by a photoplethysmography smartphone application in the general population: the ‘#PulseDay in The Netherlands’ awareness campaign
- Open Access
- 20 June 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (13) , 4401
Efficacy and Safety of Low-Dose Rivaroxaban in High-Ischemic-Risk Patients with Chronic Coronary Syndrome: Rationale and Design of the DUTCH CCS Registry
Background/Objectives: Despite progress in secondary prevention, people with chronic coronary syndrome (CCS) still face a residual risk of ischemic events. Antithrombotic therapy reduces this risk and helps stabilize chronic cardiovascular disease. Studies have shown that combining low-dose rivaroxaban with aspirin—an approach called dual-pathway inhibition (DPI)—can lower this risk and reduce major adverse cardiovascular events (MACEs). However, researchers have not yet gathered enough real-world data to confirm the efficacy and safety of this strategy. The DUTCH CCS registry aims to collect real-world data on how effective and safe low-dose rivaroxaban combined with aspirin is for patients with CCS in The Netherlands. The study aims to provide insights into the outcomes, benefits, and risks of DPI in a real-world setting, beyond the scope of controlled clinical trials. Methods: The DUTCH CCS registry operates as a national, multicenter, prospective observational study. It enrolls 1000 patients with CCS who receive rivaroxaban (2.5 mg twice daily) and aspirin (80 mg or 100 mg once daily). The study targets individuals at high ischemic risk due to coronary artery disease (CAD) and follows a single-arm design. Researchers will measure the primary efficacy endpoint by tracking MACEs, clinically driven coronary, peripheral, or carotid revascularization, and stent thrombosis over one year. They will assess the primary safety endpoint by recording major bleeding events at one year. The team will collect data at both 3-month and 1-year follow-ups. Conclusions: As an observational study, this registry is not designed to establish causality. However, it seeks to improve our understanding of how DPI performs in real-world secondary prevention for CCS patients. The results may help update treatment guidelines and inform clinical decisions in everyday practice.
- 20 June 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (13) , 4401
Open AccessEfficacy and Safety of Low-Dose Rivaroxaban in High-Ischemic-Risk Patients with Chronic Coronary Syndrome: Rationale and Design of the DUTCH CCS Registry
Background/Objectives: Despite progress in secondary prevention, people with chronic coronary syndrome (CCS) still face a residual risk of ischemic events. Antithrombotic therapy reduces this risk and helps stabilize chronic cardiovascular disease. Studies have shown that combining low-dose rivaroxaban with aspirin—an approach called dual-pathway inhibition (DPI)—can lower this risk and reduce major adverse cardiovascular events (MACEs). However, researchers have not yet gathered enough real-world data to confirm the efficacy and safety of this strategy. The DUTCH CCS registry aims to collect real-world data on how effective and safe low-dose rivaroxaban combined with aspirin is for patients with CCS in The Netherlands. The study aims to provide insights into the outcomes, benefits, and risks of DPI in a real-world setting, beyond the scope of controlled clinical trials. Methods: The DUTCH CCS registry operates as a national, multicenter, prospective observational study. It enrolls 1000 patients with CCS who receive rivaroxaban (2.5 mg twice daily) and aspirin (80 mg or 100 mg once daily). The study targets individuals at high ischemic risk due to coronary artery disease (CAD) and follows a single-arm design. Researchers will measure the primary efficacy endpoint by tracking MACEs, clinically driven coronary, peripheral, or carotid revascularization, and stent thrombosis over one year. They will assess the primary safety endpoint by recording major bleeding events at one year. The team will collect data at both 3-month and 1-year follow-ups. Conclusions: As an observational study, this registry is not designed to establish causality. However, it seeks to improve our understanding of how DPI performs in real-world secondary prevention for CCS patients. The results may help update treatment guidelines and inform clinical decisions in everyday practice.
- Open Access
- 11 April 2025
- Published by Oxford University Press (OUP) in European Heart Journal - Digital Health
- Vol. 6 (4) , 675-682
Ultra-short-term heart rate variability using a photoplethysmography-based smartphone application: a TeleCheck-AF subanalysis
Aims: Autonomic nervous system activation plays an important role in the pathophysiology of atrial fibrillation (AF). It can be determined using heart rate variability (HRV). We aimed to evaluate the feasibility of using photoplethysmography (PPG) recordings for the assessment of the ultra-short-term HRV. Methods and results: TeleCheck-AF is a structured mobile health approach, comprising the on-demand use of a PPG-based smartphone application prior to a scheduled teleconsultation to ensure comprehensive remote AF management. Participants with at least one PPG recording in sinus rhythm were included to assess resting heart rate, root mean square of successive differences (RMSSD), patient compliance and data consistency. In total, 855 patients [39.4% women] with 13 465 recordings were included. Patient compliance was 95.2% (IQR 76.2–114.3%). Median heart rate per patient was 66.5 (IQR 60.0–74.0) b.p.m., median RMSSD per patient was 40 (IQR 33–50) ms and median recording consistency was ±5.2 (IQR 3.8–7.0) b.p.m. and ±14.8 (IQR 9.3–21.1) ms, respectively. RMSSD was lower in men than women, in patients with CHA2D2-VA-Score 0, with a history of AF, and following ablation of AF. Older age and lower body mass index were associated with higher RMSSD. Conclusion: The ultra-short-term HRV can be determined in 1-min PPG recordings with high user compliance and high inter-recording consistency within a structured mobile health AF management approach. The strategy used in this study may also be feasible for the management of other conditions in which the HRV plays a role for diagnostics and therapy.
- 11 April 2025
- Published by Oxford University Press (OUP) in European Heart Journal - Digital Health
- Vol. 6 (4) , 675-682
Open AccessUltra-short-term heart rate variability using a photoplethysmography-based smartphone application: a TeleCheck-AF subanalysis
Aims: Autonomic nervous system activation plays an important role in the pathophysiology of atrial fibrillation (AF). It can be determined using heart rate variability (HRV). We aimed to evaluate the feasibility of using photoplethysmography (PPG) recordings for the assessment of the ultra-short-term HRV. Methods and results: TeleCheck-AF is a structured mobile health approach, comprising the on-demand use of a PPG-based smartphone application prior to a scheduled teleconsultation to ensure comprehensive remote AF management. Participants with at least one PPG recording in sinus rhythm were included to assess resting heart rate, root mean square of successive differences (RMSSD), patient compliance and data consistency. In total, 855 patients [39.4% women] with 13 465 recordings were included. Patient compliance was 95.2% (IQR 76.2–114.3%). Median heart rate per patient was 66.5 (IQR 60.0–74.0) b.p.m., median RMSSD per patient was 40 (IQR 33–50) ms and median recording consistency was ±5.2 (IQR 3.8–7.0) b.p.m. and ±14.8 (IQR 9.3–21.1) ms, respectively. RMSSD was lower in men than women, in patients with CHA2D2-VA-Score 0, with a history of AF, and following ablation of AF. Older age and lower body mass index were associated with higher RMSSD. Conclusion: The ultra-short-term HRV can be determined in 1-min PPG recordings with high user compliance and high inter-recording consistency within a structured mobile health AF management approach. The strategy used in this study may also be feasible for the management of other conditions in which the HRV plays a role for diagnostics and therapy.
- Open Access
- 28 March 2025
- Published by Oxford University Press (OUP) in Age and Ageing
- Vol. 54 (4)
Opportunistic screening for atrial fibrillation among frail older patients, little effort for a high diagnostic yield. Outcomes of the Dutch-GERAF study
Background and Aims: Frailty increases the risk of atrial fibrillation (AF) and its complications. This study investigated the feasibility and diagnostic yield of an eHealth screening for the detection of new AF, in frail older patients. Methods: Patients referred to the Geriatric Medicine outpatient clinics were eligible. A Frailty Index (FI) was calculated. Patients were screened for AF with electrocardiograms (ECGs) at baseline and a smartphone photoplethysmography (PPG) application, during 6 months. Results: Nine hundred fifty-two patients (median age 79 years) were included, mean FI of 0.16, 311 were frail (33%) and 751 had sinus rhythm (79%) at baseline. Six hundred forty-one patients (85%) performed PPG recordings (median 2), 295 (39%) at least 3 recordings. Twenty (2.7%) new cases of AF were found, 10 at baseline and 10 during follow-up. Among 16 (2%) patients, additional irregular PPG recordings were acquired, but no confirmatory ECG took place. Conclusion: The screening strategy proved feasible in very old and frail patients. A diagnostic yield of 2.7% was found by ECG, and an additional 0.9% of new AF cases were suspected on PPG recordings. The non-binding approach of the strategy might be disadvantageous for the patient category. Future PPG AF screening programmes for very old and frail patients should strictly organise their means of AF confirmation.
- 28 March 2025
- Published by Oxford University Press (OUP) in Age and Ageing
- Vol. 54 (4)
Open AccessOpportunistic screening for atrial fibrillation among frail older patients, little effort for a high diagnostic yield. Outcomes of the Dutch-GERAF study
Background and Aims: Frailty increases the risk of atrial fibrillation (AF) and its complications. This study investigated the feasibility and diagnostic yield of an eHealth screening for the detection of new AF, in frail older patients. Methods: Patients referred to the Geriatric Medicine outpatient clinics were eligible. A Frailty Index (FI) was calculated. Patients were screened for AF with electrocardiograms (ECGs) at baseline and a smartphone photoplethysmography (PPG) application, during 6 months. Results: Nine hundred fifty-two patients (median age 79 years) were included, mean FI of 0.16, 311 were frail (33%) and 751 had sinus rhythm (79%) at baseline. Six hundred forty-one patients (85%) performed PPG recordings (median 2), 295 (39%) at least 3 recordings. Twenty (2.7%) new cases of AF were found, 10 at baseline and 10 during follow-up. Among 16 (2%) patients, additional irregular PPG recordings were acquired, but no confirmatory ECG took place. Conclusion: The screening strategy proved feasible in very old and frail patients. A diagnostic yield of 2.7% was found by ECG, and an additional 0.9% of new AF cases were suspected on PPG recordings. The non-binding approach of the strategy might be disadvantageous for the patient category. Future PPG AF screening programmes for very old and frail patients should strictly organise their means of AF confirmation.
- Open Access
- 4 March 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (5) , e034514
Multimorbidity Is Associated With Symptom Severity and Disease Progression in Patients with Paroxysmal Atrial Fibrillation—Data From the RACE V Study
Background: Multimorbidity is common among patients with atrial fibrillation (AF) and is associated with worse outcomes. We aimed to investigate the association between multimorbidity, AF progression and AF symptom severity in patients with paroxysmal AF. Methods and Results: The RACE V (Reappraisal of AF: Interaction Between Hypercoagulability, Electrical Remodeling, and Vascular Destabilization in the Progression of AF) study included patients with paroxysmal AF and continuous rhythm monitoring. Multimorbidity was defined as ≥2 comorbidities (heart failure, hypertension, diabetes, coronary heart disease, kidney dysfunction, moderate or severe mitral valve regurgitation, or obesity). AF symptom severity was assessed via the University of Toronto AF Severity Scale questionnaire. The associations between multimorbidity, AF progression, and AF symptom severity were determined using logistic regression analyses. Median age was 65 (58–71) years and 179 of 417 patients (43%) were women, with a median of 1 (1–2) comorbidities. Median follow‐up was 2.2 (1.6–2.8) years. Multimorbidity was associated with AF progression (odds ratio [OR], 2.02 [95% CI, 1.10–3.72], P =0.024) and increased AF symptom severity (OR, 2.67 [95% CI, 1.79–3.99], P P =0.008), as well as AF symptom severity (OR, 1.64 [95% CI, 1.35–1.99], P <0.001). These results remained significant after adjusting for age. Conclusions: In patients with paroxysmal AF, multimorbidity was associated with AF progression and AF symptom severity. The risk of AF progression and AF symptom severity increased with every additional comorbidity. Registration: URL: clinicaltrials.gov . Unique Identifier: NCT02726698.
- 4 March 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (5) , e034514
Open AccessMultimorbidity Is Associated With Symptom Severity and Disease Progression in Patients with Paroxysmal Atrial Fibrillation—Data From the RACE V Study
Background: Multimorbidity is common among patients with atrial fibrillation (AF) and is associated with worse outcomes. We aimed to investigate the association between multimorbidity, AF progression and AF symptom severity in patients with paroxysmal AF. Methods and Results: The RACE V (Reappraisal of AF: Interaction Between Hypercoagulability, Electrical Remodeling, and Vascular Destabilization in the Progression of AF) study included patients with paroxysmal AF and continuous rhythm monitoring. Multimorbidity was defined as ≥2 comorbidities (heart failure, hypertension, diabetes, coronary heart disease, kidney dysfunction, moderate or severe mitral valve regurgitation, or obesity). AF symptom severity was assessed via the University of Toronto AF Severity Scale questionnaire. The associations between multimorbidity, AF progression, and AF symptom severity were determined using logistic regression analyses. Median age was 65 (58–71) years and 179 of 417 patients (43%) were women, with a median of 1 (1–2) comorbidities. Median follow‐up was 2.2 (1.6–2.8) years. Multimorbidity was associated with AF progression (odds ratio [OR], 2.02 [95% CI, 1.10–3.72], P =0.024) and increased AF symptom severity (OR, 2.67 [95% CI, 1.79–3.99], P P =0.008), as well as AF symptom severity (OR, 1.64 [95% CI, 1.35–1.99], P <0.001). These results remained significant after adjusting for age. Conclusions: In patients with paroxysmal AF, multimorbidity was associated with AF progression and AF symptom severity. The risk of AF progression and AF symptom severity increased with every additional comorbidity. Registration: URL: clinicaltrials.gov . Unique Identifier: NCT02726698.